ATE225652T1 - Fgfr3 als signal für die vorläufer der mesenchymzellen des skeletts - Google Patents

Fgfr3 als signal für die vorläufer der mesenchymzellen des skeletts

Info

Publication number
ATE225652T1
ATE225652T1 AT96917640T AT96917640T ATE225652T1 AT E225652 T1 ATE225652 T1 AT E225652T1 AT 96917640 T AT96917640 T AT 96917640T AT 96917640 T AT96917640 T AT 96917640T AT E225652 T1 ATE225652 T1 AT E225652T1
Authority
AT
Austria
Prior art keywords
fgfr3
bone
progenitor cells
skeletal progenitor
marker
Prior art date
Application number
AT96917640T
Other languages
English (en)
Inventor
Avner Yayon
Zvi Nevo
Original Assignee
Yeda Res & Dev
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Univ Ramot filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE225652T1 publication Critical patent/ATE225652T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96917640T 1995-06-12 1996-06-12 Fgfr3 als signal für die vorläufer der mesenchymzellen des skeletts ATE225652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13795P 1995-06-12 1995-06-12
PCT/IL1996/000010 WO1996041620A1 (en) 1995-06-12 1996-06-12 Fgfr3 as a marker for mesenchymal skeletal progenitor cells

Publications (1)

Publication Number Publication Date
ATE225652T1 true ATE225652T1 (de) 2002-10-15

Family

ID=21690089

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96917640T ATE225652T1 (de) 1995-06-12 1996-06-12 Fgfr3 als signal für die vorläufer der mesenchymzellen des skeletts
AT96917641T ATE213590T1 (de) 1995-06-12 1996-06-12 Fgf9 als spezifischer ligand für fgfr3

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT96917641T ATE213590T1 (de) 1995-06-12 1996-06-12 Fgf9 als spezifischer ligand für fgfr3

Country Status (12)

Country Link
US (2) US6447783B1 (de)
EP (3) EP0833620B1 (de)
JP (3) JPH11507828A (de)
CN (1) CN1195982A (de)
AT (2) ATE225652T1 (de)
AU (2) AU721773B2 (de)
CA (2) CA2223701C (de)
DE (2) DE69619526T2 (de)
DK (2) DK0836380T3 (de)
ES (2) ES2183957T3 (de)
IL (2) IL122473A (de)
WO (2) WO1996041620A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8545569B2 (en) 2001-05-25 2013-10-01 Conformis, Inc. Patient selectable knee arthroplasty devices
US9603711B2 (en) 2001-05-25 2017-03-28 Conformis, Inc. Patient-adapted and improved articular implants, designs and related guide tools
US7618451B2 (en) 2001-05-25 2009-11-17 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools facilitating increased accuracy, speed and simplicity in performing total and partial joint arthroplasty
US8556983B2 (en) 2001-05-25 2013-10-15 Conformis, Inc. Patient-adapted and improved orthopedic implants, designs and related tools
US8083745B2 (en) 2001-05-25 2011-12-27 Conformis, Inc. Surgical tools for arthroplasty
US8771365B2 (en) 2009-02-25 2014-07-08 Conformis, Inc. Patient-adapted and improved orthopedic implants, designs, and related tools
US7468075B2 (en) 2001-05-25 2008-12-23 Conformis, Inc. Methods and compositions for articular repair
US8480754B2 (en) 2001-05-25 2013-07-09 Conformis, Inc. Patient-adapted and improved articular implants, designs and related guide tools
US8735773B2 (en) 2007-02-14 2014-05-27 Conformis, Inc. Implant device and method for manufacture
US8882847B2 (en) 2001-05-25 2014-11-11 Conformis, Inc. Patient selectable knee joint arthroplasty devices
US7534263B2 (en) 2001-05-25 2009-05-19 Conformis, Inc. Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty
US8617242B2 (en) 2001-05-25 2013-12-31 Conformis, Inc. Implant device and method for manufacture
US6136040A (en) * 1998-03-05 2000-10-24 Washington University Animal model with disrupted FGF-9 gene
ATE439806T1 (de) 1998-09-14 2009-09-15 Univ Leland Stanford Junior Zustandsbestimmung eines gelenks und schadenvorsorge
US7239908B1 (en) 1998-09-14 2007-07-03 The Board Of Trustees Of The Leland Stanford Junior University Assessing the condition of a joint and devising treatment
US20020058036A1 (en) * 1999-07-27 2002-05-16 Michael Jeffers Novel fibroblast growth factor and nucleic acids encoding same
US7482114B2 (en) 1999-10-06 2009-01-27 Tigenix N.V. In vivo assay and molecular markers for testing the phenotypic stability of cell populations, and selected cell populations for autologous transplantation
ATE285797T1 (de) 1999-10-06 2005-01-15 Tigenix Nv In vivo assay zur prüfung der phänotypischen stabilität
CA2386506C (en) 1999-10-06 2012-02-21 Tigenix N.V. Isolation of precursor cells and their use for tissue repair
WO2001060850A1 (en) * 2000-02-14 2001-08-23 Smithkline Beecham Corporation Novel compounds
US20020037557A1 (en) * 2000-03-13 2002-03-28 Amgen, Inc. Fibroblast growth factor-like molecules and uses thereof
DE60136474D1 (de) 2000-09-14 2008-12-18 Univ R Beurteilung des zustandes eines gelenkes und des verlustes von knorpelgewebe
ATE426357T1 (de) 2000-09-14 2009-04-15 Univ Leland Stanford Junior Beurteilung des zustandes eines gelenkes und planung einer behandlung
US20040110177A1 (en) * 2001-02-02 2004-06-10 Axel Ullrich Method for identifying functional nucleic acids
US8439926B2 (en) 2001-05-25 2013-05-14 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools
CA2447694A1 (en) 2001-05-25 2002-12-05 Imaging Therapeutics, Inc. Methods and compositions for articular resurfacing
WO2002102972A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003076467A1 (en) * 2002-03-14 2003-09-18 Yeda Research And Development Co. Ltd. Compositions and methods for inducing and regulating bone formation
WO2004022095A1 (en) * 2002-09-04 2004-03-18 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
EP1555962B1 (de) 2002-10-07 2011-02-09 Conformis, Inc. Minimal invasives gelenkimplantat mit einer den gelenkflächen angepassten dreidimensionalen geometrie
CA2505371A1 (en) 2002-11-07 2004-05-27 Conformis, Inc. Methods for determining meniscal size and shape and for devising treatment
AU2011211453B2 (en) * 2004-06-21 2015-01-15 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
EP2453024B1 (de) 2004-06-21 2017-12-06 The Board of Trustees of The Leland Stanford Junior University Differenziell exprimierte Gene und Leitungsbahnen bei bipolarer Störung und/oder schwerer depressiver Erkrankung
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
ES2710099T3 (es) * 2004-09-24 2019-04-23 Mesoblast Inc Progenie de células precursoras mesenquimales expandidas multipotenciales (MEMP) y sus usos
US7391676B2 (en) * 2004-12-22 2008-06-24 Asml Netherlands B.V. Ultrasonic distance sensors
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
US20070049739A1 (en) * 2005-08-30 2007-03-01 Biomet Manufacturing Corp. Method and system for extracting blood-derived growth factors
TWI584796B (zh) 2006-02-06 2017-06-01 康福美斯公司 患者可選擇式關節置換術裝置及外科工具
US8623026B2 (en) 2006-02-06 2014-01-07 Conformis, Inc. Patient selectable joint arthroplasty devices and surgical tools incorporating anatomical relief
EP2119767B1 (de) * 2007-01-23 2016-01-20 Yokohama City University Verfahren zur präparation einer knorpelzelle
WO2008157412A2 (en) 2007-06-13 2008-12-24 Conformis, Inc. Surgical cutting guide
US8682052B2 (en) 2008-03-05 2014-03-25 Conformis, Inc. Implants for altering wear patterns of articular surfaces
WO2009140294A1 (en) 2008-05-12 2009-11-19 Conformis, Inc. Devices and methods for treatment of facet and other joints
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8808297B2 (en) 2009-02-24 2014-08-19 Microport Orthopedics Holdings Inc. Orthopedic surgical guide
US9017334B2 (en) 2009-02-24 2015-04-28 Microport Orthopedics Holdings Inc. Patient specific surgical guide locator and mount
US8808303B2 (en) 2009-02-24 2014-08-19 Microport Orthopedics Holdings Inc. Orthopedic surgical guide
EP2405865B1 (de) 2009-02-24 2019-04-17 ConforMIS, Inc. Automatisierte systeme zur herstellung von individuell an den patienten angepassten implantaten und instrumenten
SG174904A1 (en) 2009-03-25 2011-11-28 Genentech Inc Anti-fgfr3 antibodies and methods using same
SG10201401326SA (en) 2009-04-16 2014-10-30 Conformis Inc Patient-specific joint arthroplasty devices for ligament repair
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
CA2782137A1 (en) 2009-12-11 2011-06-16 Conformis, Inc. Patient-specific and patient-engineered orthopedic implants
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
WO2012112698A2 (en) 2011-02-15 2012-08-23 Conformis, Inc. Patient-adapted and improved articular implants, procedures and tools to address, assess, correct, modify and/or accommodate anatomical variation and/or asymmetry
US9486226B2 (en) 2012-04-18 2016-11-08 Conformis, Inc. Tibial guides, tools, and techniques for resecting the tibial plateau
US9675471B2 (en) 2012-06-11 2017-06-13 Conformis, Inc. Devices, techniques and methods for assessing joint spacing, balancing soft tissues and obtaining desired kinematics for joint implant components
KR20160002681A (ko) 2013-01-16 2016-01-08 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
AU2014232030B2 (en) 2013-03-10 2016-05-26 National University Corporation Nagoya University Therapeutic agent for systemic bone disease and use thereof
SI3481859T1 (sl) 2016-07-07 2022-07-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Topni polipeptidi receptorja 3 fibroblastnega rastnega faktorja (SFGFR3) in njihove uporabe
US12108959B2 (en) 2019-05-29 2024-10-08 Wright Medical Technology, Inc. Preparing a tibia for receiving tibial implant component of a replacement ankle
JP2020015733A (ja) * 2019-08-19 2020-01-30 アンセルムＩｎｓｅｒｍ 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
IT201900025126A1 (it) * 2019-12-20 2021-06-20 Sildeha Swiss S A Uso di derivati dell’acido ialuronico nella rigenerazione dei tessuti ossei e cartilaginei
CN116162589A (zh) * 2022-12-30 2023-05-26 西北工业大学 干细胞及其制备方法和应用、及标记组合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5226914A (en) * 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5270197A (en) 1990-12-20 1993-12-14 The Children's Medical Center Corporation Cells expressing a substantial number of surface high affinity HBGF receptors but relatively few low affinity HBGF binding sites and system for assaying binding to HBGF receptor
JP3385040B2 (ja) * 1991-02-14 2003-03-10 武田薬品工業株式会社 グリア活性化因子およびその製造法
EP0608546A3 (en) 1992-12-22 1995-09-27 Takeda Chemical Industries Ltd Glia activating factor (gaf), antibodies against it and their uses.
WO1994021813A1 (en) * 1993-03-17 1994-09-29 The Whittier Institute For Diabetes And Endocrinology Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof

Also Published As

Publication number Publication date
IL122472A (en) 2003-11-23
IL122473A (en) 2003-11-23
EP0836380B1 (de) 2002-02-27
IL122473A0 (en) 1998-06-15
JP3673281B2 (ja) 2005-07-20
AU6014496A (en) 1997-01-09
US20020193309A1 (en) 2002-12-19
CN1195982A (zh) 1998-10-14
JPH11507828A (ja) 1999-07-13
AU6014596A (en) 1997-01-09
ES2173289T3 (es) 2002-10-16
WO1996041523A1 (en) 1996-12-27
US6447783B1 (en) 2002-09-10
WO1996041620A1 (en) 1996-12-27
DE69619526T2 (de) 2002-10-31
EP0833620A4 (de) 1998-05-06
AU721773B2 (en) 2000-07-13
EP1342476A2 (de) 2003-09-10
JPH11508358A (ja) 1999-07-21
DK0833620T3 (da) 2003-01-13
DE69619526D1 (de) 2002-04-04
ATE213590T1 (de) 2002-03-15
CA2224229A1 (en) 1996-12-27
DE69624239D1 (de) 2002-11-14
DE69624239T2 (de) 2003-07-10
EP0836380A1 (de) 1998-04-22
EP0836380A4 (de) 1999-03-31
DK0836380T3 (da) 2002-04-22
ES2183957T3 (es) 2003-04-01
JP2004305221A (ja) 2004-11-04
CA2223701A1 (en) 1996-12-27
EP1342476A3 (de) 2003-09-17
CA2223701C (en) 2010-02-16
EP0833620B1 (de) 2002-10-09
IL122472A0 (en) 1998-06-15
EP0833620A1 (de) 1998-04-08
AU715996B2 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
ATE225652T1 (de) Fgfr3 als signal für die vorläufer der mesenchymzellen des skeletts
Persson et al. Sutural closure in rabbit and man: a morphological and histochemical study.
ATE156365T1 (de) Osteogenische wachstumsfaktoren zur abgabe an zielorgan
ATE198980T1 (de) Bioabbaubare polymere zur zelltransplantation
AR009742A1 (es) Aminoacidos modificados, medicamentos que contienen estos compuestos y procedimiento para su preparacion
NZ225344A (en) 3-demethylmevalonic acid derivatives and lactones and pharmaceutical compositions; intermediates for the preparation thereof
DE69435198D1 (de) "hedgehog-like" proteine von wirbeltieren, die embryonale strukturen induzieren
DE69632401D1 (de) Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung
DE69620877D1 (de) Arzneimittelformulierungen für il-12
ES2157116T3 (es) Composiciones de teñido de fibras queratinicas que contienen 3-aminopirazolo-(1,5-a)-pirimidinas, procedimiento de teñido, 3-aminopirazolo-(1,5-a)-pirimidinas y su procedimiento de preparacion.
HK1033582A1 (en) Antibodies to death receptor 4 (dr4) and uses thereof
AP9801269A0 (en) Prostaglandin agonists.
YU72594A (sh) Vodeni rastvor inkluzionih kompleksa benzotiofen jedinjenja sa vodorastvornim ciklodekstrinima, njegove farmaceutske formulacije i postupci za dobijanje
IL141877A0 (en) Pharmaceutical compositions containing alpha4 integrin antagonists
WO1999051186A3 (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
ATE222122T1 (de) Verfahren zur tötung von zielzellen in geernteten zellpopulationen mit hilfe von zwei immunotoxinen
CA2069638A1 (en) Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands
DE69737455D1 (de) Definierte systeme zur kultivieurng epithelialer zellen und anwendung derselben
ES2056639T3 (es) Procedimiento para la transformacion del acido (benzoil-3 fenil)-2 propionico-r(-) en isomero s(+).
Hernandez-Vidal et al. Immunolocalization of cathepsin B in equinedyschondroplastic articular cartilage
ATE17738T1 (de) Mitogene aus leukozyten und entzuendeten geweben: natuerliche leukopoietische proteine fuer die spezifische induktion der vermehrung und der differenzierung von leukozyten; verfahren zu ihrer biotechnischen herstellung und pharmazeutische zusammensetzungen.
ATE222901T1 (de) Carboxylsubstituierte chromanderivate zur verwendung als beta 3 adrenorezeptor-agonisten
TR200000444T2 (tr) 3-Aril-süksinamido-hidroksamik asitler, üretim yöntemleri ve bu maddeleri içeren farmasötik terkipler.
PL361732A1 (en) Use of a biological material containing three-dimensional scaffolds of hyaluronic acid derivatives for the preparation of implants in arthroscopy and kit for instruments for implanting said biological material by arthroscopy
ATE106883T1 (de) Azelastin-embonat, verfahren zu seiner herstellung und pharmazeutische zubereitungen, die als wirkstoff azelastin-embonat enthalten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0833620

Country of ref document: EP

REN Ceased due to non-payment of the annual fee